CD8A and neoplasm: This strategy, aimed at overcoming the immunosuppressive tumor microenvironment, significantly enhances the infiltration of CD8 (+) T cells into the tumor and activates dendritic cells in sentinel lymph nodes, leading to inhibited tumor growth and a 40% cure rate in a preclinical model.